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Abstract The most common chromosomal aberrations
in myelodysplastic syndromes (MDS) are complete or
partial loss of chromosomes 5 and 7, and trisomy 8. To
identify genes important in the pathogenesis of this dis-
ease that could be associated with these gross chromos-
omal defects, we have employed the differential display
PCR (DDPCR) procedure developed by Liang and
Pardee. This method allows simultaneous comparison
of several cDNA sources for the presence of differen-
tially expressed genes. Polymorphonuclear cells
(PMNs) from two MDS patients, containing a 5q dele-
tion or a trisomy 8, and three healthy controls were
used. Initial screening resulted in the identification of
five and three partial cDNA sequences, respectively
that were either differentially expressed in both patient
samples or in individual patients, as compared with the
controls. The authenticity of aberrant expression was
verified by reanalyzing the same primer combinations
on newly prepared cDNA. Differential expression of
the three remaining fragments was subsequently
checked on a larger panel of MDS patients, using am-
plicon-specific primer sets. These were obtained by
cloning and sequencing of the fragments. For one par-
tial cDNA (DC3), the original expression pattern, i.e.,
decreased expression in individual MDS patients, was
confirmed. These results demonstrate the utility of the
DDPCR procedure to isolate differentially expressed
sequences in primary patient samples where the availa-
bility of cells is a limiting factor.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogene-
ous group of clinically defined disorders characterized
by ineffective hematopoiesis and involving at least two
myeloid lineages. Patients with MDS show peripheral
blood cytopenia and a normocellular or hypercellular
bone marrow with signs of defective maturation. A
classification into five subgroups has been made by the
French-American-British (FAB) Cooperative Study
Group, based on the number of blast cells in peripheral
blood and bone marrow and the number of peripheral
blood monocytes [1]. Chromosomal abnormalities are
observed in the bone marrow of 40–50% of MDS pa-
tients unrelated to previous therapy [11]. The most
common abnormalities are loss of a part of chromo-
some 5q, monosomy 7, and trisomy 8.
It is generally accepted that the MDS are clonal dis-
orders involving myeloid cells. However, X-chromo-
some inactivation studies on the clonal nature of lym-
phopoiesis have shown ambiguous results. Some re-
ports have described a clonal involvement of lymphoid
cells [17], whereas we have demonstrated that T lym-
phocytes, B lymphocytes, and natural killer cells are
polyclonal [18]. Furthermore, studies on the occurrence
of chromosome 5, 7, and 8 aberrations have demon-
strated that they are also restricted to cells of myeloid
origin [5–7].
Because the most common genetic defects in MDS
involve gross chromosomal aberrations, it is extremely
difficult to identify the gene(s) which might play a role
in the pathogenesis of the disease. In case of the 5q del-
etions, the critical region defined at 5q31-q33 [8] is still
too large to allow pinpointing of the responsible tumor-
suppressor gene(s). Moreover, a simple genetic ap-
proach to analyzing the aneuploidies is not at hand. An
alternative procedure would be analysis of differences
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in gene expression between normal and aberrant cells.
This can be accomplished by the conventional subtrac-
tive hybridization technique [9] that has, for example,
been successfully applied to identify maspin, a gene
with tumor-suppressing activity in human mammary
epithelial cells [20]. However, this method allows com-
parison of only two cell sources per experiment and re-
quire relatively large amounts of RNA. These draw-
backs can be overcome by using the differential display
PCR (DDPCR) procedure [10], which has allowed the
identification of aberrantly expressed genes in breast
and brain tumors [14, 15]. The general strategy of this
method is PCR amplification of subsets of cDNA, as
obtained by reverse transcription of total RNA with an-
chored poly(dT)12 primers. As PCR primers, the appro-
priate anchored poly(dT)12 and short (10-mers) ran-
dom oligomers are used. The resulting expression pat-
terns obtained from various cell sources are simulta-
neously analyzed by displaying the generated short
cDNA fragments on denaturing PAA gels.
In order to test its potential application in MDS, we
have performed a pilot study to detect differentially ex-
pressed genes in two MDS patients, one with a chromo-
some 5 deletion and the other with a trisomy 8, as com-
pared with control samples from three healthy individ-
uals. As cell sources, purified polymorphonuclear cells
(PMNs) were used, since they were shown to contain
the genetic defects [6, 7]. Both partial cDNA sequences
that were differentially expressed in the individual pa-
tients or aberrantly expressed in both patients were
analyzed. Because of the limited material available,
Northern analysis could not be applied to unambi-
guously show aberrant expression of a given fragment.
Several PCR-based control experiments were therefore
included to confirm the authenticity of differential ex-
pression.
Materials and methods
Patients
Two MDS patients were analyzed. The first patient (UPN 1) was
a 67-year-old women, who suffered from refractory anemia (RA).
Cytogenetic analysis on GTG-banded metaphases demonstrated
a deletion of the long arm of chromosome 5 in 90% of her bone
marrow cells. The other patient (UPN 2), a 43-year-old man, was
diagnosed as having myeloproliferative syndrome (MPS) and had
a trisomy 8 in all bone marrow cells. Five other MDS patients
were used in a second screening to confirm differential expression
of partial cDNA sequences. Two of them had RA (UPN 4 and 6),
two RA with excess of blasts (RAEB, UPN 3 and 7), and one was
unclassified (UPN 5). UPN 3, 5, and 6 were cytogenetically nor-
mal, whereas UPN 4 and 7 had deletions of the long arm of chro-
mosome 5 in 90–100% of their bone marrow cells.
Cell separation and RNA extraction
Thirty milliters of EDTA blood was used to obtain PMNs by Fi-
coll-isopaque density gradient separation (1.077 g/cm2). Total cel-
lular RNA was isolated from these cells by the guanidium-thio-
cyanate-phenol-chloroform extraction procedure, as described
previously [4]. In case RNA was isolated from fewer than 1!106
cells, 25 mg glycogen was added as a carrier.
The chromosomal DNA was removed by incubation for
30 min at 37 7C with 10 units of ribonuclease inhibitor (BRL, Gai-
therburg, Md., USA), 10 units DNAse I (BRL) in 10 mM Tris-
HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2. After extraction with
phenol/CHCl3 (3 :1), the RNA in the aqueous layer was precipi-
tated and dissolved in water.
Differential display PCR
cDNA subsets were prepared using three of the 12 possible an-
chored poly(dT)12 primers (T12AG, T12CC, and T12GC). The
reactions were performed as described by Liang and Pardee [10],
with some minor modifications. For each cDNA synthesis, RNA
isolated from 2!104 PMNs were reverse transcribed using 10
units of MMLV reverse transcriptase (BRL) for 60 min at 37 7C.
The reaction mixture (20 ml) further contained 1 mM of one of the
anchored poly(dT)12 primers, 20 mM dNTP, 50 mM Tris, 75 mM
KCl, 3 mM MgCl2, and 10 mM DTT, pH 8.3.
The PCR amplifications (20 ml each) were performed on 2 ml
of heat-inactivated reverse transcriptase mixture, using combina-
tions of an arbitrary 10-mer primer and the appropriate anchored
poly(dT)12 primer (1 mM each), in the presence of 2 mM of each
dNTP, 0.25 mM [a-35S]dATP (1000 Ci/mmol; Amersham, UK),
2 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 0.02% BSA,
and 1 unit of Taq polymerase (AmpliTaq; Cetus, Calif., USA).
Following an initial denaturation at 95 7C for 5 min, the samples
were amplified for 40 cycles of incubation at 95 7C for 0.5 min,
40 7C for 2 min, and 72 7C for 1 min. The reaction products were
analyzed on 6% polyacrylamide (PAA) denaturing gels. The
dried gels were exposed for at least 16 h to X-ray films.
Verification of differential expression of cDNA fragments
First, the specificity was tested by repeating the DDPCR on new-
ly prepared cDNA. The partial cDNAs that were still differential-
ly expressed were excised from the dried gels, boiled in 100 ml
H2O for 10 min, and re-amplified, using the conditions described
above, but now in the presence of 2.5 mM dNTP and without [a-
35S]dATP. These PCR products were cloned into pCR1000 using
the TA cloning system (Invitrogen, San Diego, Calif., USA). To
check the size of the recombinant clones, the inserts were ream-
plified for ten cycles and analyzed on denaturing gels, which also
contained the original display PCR samples from the patients and
controls. Only the cloned fragments that co-migrated with the dif-
ferentially expressed fragments were sequenced using a sequence
kit (Boehringer Mannheim Biochemicals, Mannheim, Germany)
according to descriptions provided by the supplier. Computer
searches against the sequences in database GenBank (dated Jan-
uary 1, 1996) were performed to check for homology. Based on
the sequence, nested 20-mer primers were synthesized that al-
lowed verification of the differential expression by PCR amplifi-
cation using the specific primer sets. For this purpose, cDNA was
prepared by reverse transcription with poly(dT)18 from 2 mg
RNA of the same patient, the patients of the second screening
panel, and control samples.
The chromosomal localization of individual partial cDNAs
was determined by PCR analysis of the human-rodent somatic
cell hybrid mapping panel 2 (NIGMS), using the amplicon-specif-
ic primers. This panel consists of DNA isolates from 24 hybrids,
each retaining a single intact human chromosome.
Results
Validation of the DDPCR method using small cell
numbers
The differential display technique was originally de-
scribed to detect differently expressed genes from cell
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lines [10]. We have used purified PMNs to compare ex-
pression patterns between MDS patients and healthy
controls. Due to the limited number of patient cells
available, the procedure had to be scaled down with re-
spect to cell numbers and amount of RNA that could
be analyzed. RNA was isolated from 1!102 to 1!106
cells in the presence of 25 mg tRNA or 25 mg glycogen.
Reproducible patterns on denaturing PAA gels were
obtained when at least 2!104 cells were used. This is
one order of magnitude lower than originally de-
scribed, assuming that 0.02 m g RNA can be isolated
from these cells. When lower cell numbers were used,
patterns of lower complexity were obtained in each
PCR reaction. Also at the level of PCR amplification, a
tenfold dilution of the cDNA samples was used effec-
tively without loss of information. Equally good results
were obtained with both types of carriers. For further
experiments glycogen was used because of the potential
interference of tRNA in the amplification step.
Initial screening of MDS samples using differential
display PCR
Using the adaptations described above, total RNA
samples from PMNs of three healthy individuals and of
the two MDS patients were analyzed. To date, 20 com-
binations of arbitrary 10-mer and anchored poly(dT)12
primers have been tested. Each primer combination re-
vealed 50–100 different PCR fragments on denaturing
PAA gels. The expression profiles for the individual
PCR reactions were largely identical between the pa-
tient and control samples. Only minor differences were
observed (Fig. 1). Five partial cDNA sequences were
identified which were either absent or present in both
MDS patients as compared with the healthy controls
(see, for example, Fig. 2a), while three other fragments
were differentially expressed in individual patients
(Fig. 2b).
It should be noted that the fragments were often
present as doublets in the denaturing PAA gels. Se-
quence analysis of both fragments and gel migration
analysis of the cloned fragments (see below) revealed
that this phenomenon is due to small differences in the
electrophoretic mobility of the two complementary
DNA strands.
Analysis of the authenticity of aberrantly expressed
fragments
Because of the limited amount of RNA available, we
were not able to perform Northern analysis to unambi-
guously show aberrant expression of a given fragment.
Several PCR-based control experiments were therefore
included to check the authenticity of differential ex-
pression. The specificity was first verified by reanalyz-
ing the same primer combinations on newly prepared
Fig. 1 Display of partial cDNAs on 6% PAA denaturing gels for
two primer combinations (subsets 1 and 2). Lanes 1–3, PMNs of
healthy controls; lanes 4, 5, PMNs from MDS patients
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Fig. 2a, b Examples of differ-
entially expressed cDNA frag-
ments. a DC5 (arrow) is pres-
ent in both patients, UPN 1
(P1) and UPN 2 (P2), but ab-
sent in the healthy controls
(C1 and C2). b DC3 (arrows)
is absent in UPN 1, but pres-
ent in UPN 2 and the healthy
controls
a b
cDNAs. Two fragments (DC5, 467 bp, and DC7,
393 bp) were reproducibly aberrantly expressed in both
MDS patients, whereas one cDNA fragment (DC3,
215 bp) was reproducibly absent in the patient with a
5q deletion (UPN 1). For further characterization, the
individual bands were recovered from the dried se-
quencing gels, reamplified using the corresponding
primer sets, and cloned into the pCR1000 plasmid vec-
tor. To eliminate false-positive clones, they were first
checked by fractionation on denaturing PAA gels
alongside the original DDPCR products. For example,
in case of DC3, only three of six clones tested were of
the correct length. Clones containing the DC5, DC7,
and DC3 PCR products were subsequently sequenced
(e.g., Fig. 3). Genbank searches revealed that DC5 was
identical to an anonymous fragment isolated from a
muscle cDNA library. For the other two fragments no
similarities were found; therefore, they could represent
uncharacterized genes. All fragments were flanked by
the arbitrary 10-mer primers, rather than by a 10-mer
and an anchored poly(dT)12 primer. This is possibly
due to the ratio between the arbitrary primer and an-
chored poly(dT)12 used, which was fivefold higher, as
described previously [10].
Fig. 3 Partial nucleotide sequence of the DC3 cDNA clone. The
arbitrary 10-mer primer used is underlined twice and the ampli-
con-specific 20-mer primers are underlined once
For the three remaining fragments, amplicon-specif-
ic primer sets (20-mers) were synthesized (e.g., Fig. 3,
underlined). These nested primers were used to ascer-
tain the differential expression by amplification of po-
ly(dT)18 cDNA from the same patient, two control sam-
ples, and the five MDS patients of the secondary panel.
Only in the case of DC3 it was possible to confirm dif-
ferential expression in this way. The amplicon was pres-
ent in PMNs from normal controls, and decreased in
intensity or barely detectable in those from five of the
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Fig. 4 Nested PCR with amplicon-specific primers to confirm the
differential expression of DC3 in PMNs of two healthy controls
(C1, C2), UPN 1 (P1), and the five other MDS patients (P3-P7)
six MDS patients after 35 rounds of amplification
(Fig. 4).
The chromosomal localization of DC3 was deter-
mined by PCR of DNA isolates from 24 hybrid cell
lines of a mapping panel with the specific 20-mers. This
revealed that DC3 localizes to chromosome 3 (data not
shown).
Discussion
Only a handful of genes involved in the pathogenesis of
MDS have been identified. In the majority of cases,
these genes were implicated in structural chromosomal
aberrations such as translocations and inversions and
were identified following labor-intensive molecular ge-
netic approaches. For the numerical abnormalities ob-
served in MDS these procedures are not applicable.
Recently, the DDPCR technique has been develop-
ed, allowing direct comparison of expression patterns
between tumor and normal cells. This procedure has
proven useful for the isolation of differentially ex-
pressed genes in several cell lines derived from tumors
[14, 15]. We have tested whether the method could also
be applied to purified primary cells from MDS patients.
This meant that the procedure had to be scaled down
with respect to the cell numbers required. Furthermore,
several controls (preferably PCR based) were included
to verify aberrant expression of the partial cDNAs de-
tected during the primary screens. For example, RT-
PCR with fragment-specific nested primers was per-
formed, rather than Northern hybridization. Another
important issue was the elimination of false-positive
fragments following cloning of differentially expressed
fragments through fractionation on denaturing PAA
gels alongside the original DDPCR sample. An alterna-
tive procedure has been described by Callard et al. [3],
who reduced the number of contaminating sequences
by hybridization of the purified PCR products to dot-
blots containing the cloned fragments.
We have compared the expression patterns of purif-
ied PMNs from two MDS patients with those of healthy
individuals. The expression fingerprints obtained with
individual primer combinations were almost identical
for the different samples. So far, 20 primer combina-
tions have been tested in this pilot study. If we assume
that a given cell type expresses 15000 different mRNAs
on average, and one PCR amplification generates 50–
100 cDNA fragments, about 1/10 mRNAs expressed in
PMNs have been screened. Of them, three were consis-
tently aberrantly expressed, either in both patients
(DC5 and DC7) or in an individual patient (DC3).
The decreased expression of DC3 in the patient with
the 5q deletion (UPN 1) was confirmed by PCR with
specific primers on poly(dT) cDNA. Also in the sec-
ondary panel of MDS patients the expression level was
decreased or barely detectable in most of the samples,
indicating that this gene could be disregulated in MDS.
Altered RNA expression levels in a subset of MDS pa-
tients have been observed for a variety of genes, such
as multidrug resistance P-glycoprotein [16], c-mpl [19],
c-fms, c-kit, and flt3 [2]. We can assume that the major-
ity of them represent a common consequence of dys-
regulated growth and are not directly involved in leu-
kemogenesis. DC3 maps to chromosome 3, as was
shown using the human-rodent hybrid mapping panel.
This localization could be of interest, since several
known MDS-related genes, such as Evi-1, EAP, and
MDS-1, are known to be clustered here [12, 13].
In conclusion, differential display PCR has proven
to be an elegant procedure that allows simultaneous as-
sessment of multiple primary patient samples to identi-
fy aberrantly expressed cDNA sequences. With respect
to DC3, isolation of the full-length cDNA could pro-
vide insight into its potential role in the pathogenesis of
MDS.
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